Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Autoimmune Blistering Diseases Study
-
Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania, United States, 19104
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania, United States, 19104
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
University of Pennsylvania,
2025-01-02